Clinical Trial Transparency

Clinical trial transparency is the umbrella principle that every clinical trial's existence, design, and outcome should be made public regardless of what the results show. A given practice counts as advancing clinical trial transparency when it does at least one of three things: (1) makes a trial discoverable before it enrolls participants (prospective registration in a WHO-recognized registry such as ClinicalTrials.gov, ISRCTN, or EU CTIS), (2) makes that trial's summary results discoverable after it ends, including when results are negative, null, or unfavorable to the sponsor (results reporting, most concretely enforced in the US through FDAAA 801 and its implementing regulation, 42 CFR Part 11), or (3) makes the underlying protocol, statistical analysis plan, or individual participant-level data available for independent scrutiny (clinical data sharing). It is a movement and a set of overlapping obligations and voluntary commitments, not a single regulation -- a trial can satisfy one pillar (say, registration) while failing another (results reporting), which is precisely the gap transparency advocacy has spent over a decade trying to close.

ByCASRAI Editorial Board

· Last updated 23 Jul 2026

Worked examples

Is an instance

A pharmaceutical sponsor registers a Phase 3 trial on ClinicalTrials.gov before the first participant is enrolled, then -- whether the drug beats placebo or not -- submits summary results to the registry within the FDAAA 801/42 CFR Part 11 deadline. Both the existence of the trial and its outcome are now part of the public record, closing off the possibility that a disappointing result simply never surfaces.

Is an instance

A funder or journal requires, as a condition of funding or publication, that a completed trial's individual participant-level data (de-identified) be deposited in a repository or made available on request to qualified researchers, per initiatives such as the ICMJE data-sharing statement requirement or funder-level open-data policies -- extending transparency beyond the registry summary to the data that would let another researcher independently re-analyze the trial.

Is an instance

An advocacy coalition -- most prominently the AllTrials campaign, launched in the UK in January 2013 by Ben Goldacre and Sense About Science together with the BMJ, Cochrane Collaboration, PLOS, and other partners -- publicly petitions for a policy standard that every past and future trial be registered and have its full methods and results reported, arguing that non-reporting biases the evidence base clinicians and regulators rely on.

Looks similar, but isn't

Not an instance

A trial is registered on ClinicalTrials.gov before enrollment (satisfying registration) but its sponsor never submits summary results after completion, and the trial's outcome is not published in any journal either -- a documented and common failure mode across sponsor types that transparency advocacy specifically targets, since registration alone does not guarantee the result is ever discoverable.

Not an instance

A completed trial's positive results are published promptly in a journal, but its raw or negative-arm data is withheld from any repository and not registered at all before enrollment -- selective, after-the-fact disclosure of favorable findings is the opposite of transparency in this sense, even though something about the trial did become public.

Clinical trial transparency as an umbrella principle

“Clinical trial transparency” is not itself a single law or standard — it is the organizing principle behind several distinct, real obligations and initiatives that together aim at one outcome: that no clinical trial’s existence or outcome disappears from the public record simply because a sponsor, investigator, or journal chooses not to report it. CASRAI treats it as an umbrella term covering three pillars, plus the advocacy movement that has pushed to close gaps between them.

The three pillars

1. Prospective registration

A trial is registered in a recognized public registry (ClinicalTrials.gov, ISRCTN, the EU’s Clinical Trials Information System, or another WHO International Clinical Trials Registry Platform primary registry) before the first participant is enrolled. This is the entry point for transparency: it establishes, on the record, that a trial exists and what it intends to measure, which is what makes later non-reporting detectable at all. See CASRAI’s Clinical Trial Registration and Prospective Clinical Trial Registration entries for how registration timing and registry choice work in practice.

2. Results reporting

Once a trial concludes, summary results — not just a journal publication, but structured outcome data submitted directly to the registry — are made public, whether the trial succeeded, failed, or was stopped early. In the US, this is a binding legal requirement for an “applicable clinical trial” under FDAAA 801 and its implementing regulation, 42 CFR Part 11, with statutory civil penalties for noncompliance; see CASRAI’s 42 CFR Part 11 entry and the Clinical Trial Registration and Reporting Compliance guide for the registration/results-reporting mechanics and deadlines in full, including how FDAAA’s “applicable clinical trial” definition differs from NIH’s and ICMJE’s broader ones. Results-reporting obligations are the pillar most often unmet in practice: a trial can be dutifully registered and still never have its results submitted, which is exactly the failure mode transparency advocacy targets.

3. Data sharing

Beyond the registry’s structured summary, some funders, journals, and voluntary commitments call for sharing the underlying protocol, statistical analysis plan, or de-identified individual participant-level data, so an independent researcher can verify or re-analyze a trial’s findings rather than take the summary result at face value. See CASRAI’s Data Sharing Policy guide and Data Sharing Agreement entry for how these commitments are typically structured and governed.

The advocacy dimension: why transparency became a movement

The three pillars above exist as formal obligations today partly because of sustained advocacy pressure. The best-known campaign is AllTrials, launched in the UK in January 2013 by physician and writer Ben Goldacre together with Sense About Science, and backed by an international coalition including the BMJ, the Cochrane Collaboration, PLOS, and the James Lind Initiative. AllTrials’ central argument is that publication bias — the tendency for positive or favorable trial results to be reported far more often than negative or null ones — distorts the evidence base that clinicians, regulators, and systematic reviewers rely on, and that the only reliable fix is a policy standard requiring every trial, past and present, to be registered with its full methods and results reported. The campaign helped shift transparency from a matter of individual researcher or sponsor discretion toward the kind of binding registry-level requirement now embodied in FDAAA 801/42 CFR Part 11 and funder data-sharing mandates, even though full retrospective compliance for older trials remains an acknowledged, unresolved gap.

Why the distinction between pillars matters operationally

For a research administrator or compliance officer, the practical value of treating “transparency” as three separable pillars rather than one checkbox is that each has its own owner, deadline, and enforcement mechanism — a sponsor can be fully compliant on registration and still be delinquent on results reporting, or compliant on both while sharing no underlying data at all. Auditing or reporting on “clinical trial transparency” as an institutional metric means checking all three, not just the one that happens to be easiest to verify. See CASRAI’s Clinical Trial Disclosure Services guide for how institutions and sponsors typically operationalize registration and results submission across a trial portfolio.

Related terms

Use in your systems

JATS XML <role> element

xml

<role vocab="credit"
      vocab-identifier="https://casrai.org/dictionary/"
      vocab-term="Clinical Trial Transparency"
      vocab-term-identifier="https://casrai.org/dictionary/term/clinical-trial-transparency" />

Schema.org DefinedTerm (JSON-LD)

json

{
  "@context": "https://schema.org",
  "@type": "DefinedTerm",
  "@id": "https://casrai.org/dictionary/term/clinical-trial-transparency",
  "name": "Clinical Trial Transparency",
  "identifier": "https://casrai.org/dictionary/term/clinical-trial-transparency",
  "description": "Clinical trial transparency is the umbrella principle that every clinical trial's existence, design, and outcome should be made public regardless of what the results show. A given practice counts as advancing clinical trial transparency when it does at least one of three things: (1) makes a trial discoverable before it enrolls participants (prospective registration in a WHO-recognized registry such as ClinicalTrials.gov, ISRCTN, or EU CTIS), (2) makes that trial's summary results discoverable after it ends, including when results are negative, null, or unfavorable to the sponsor (results reporting, most concretely enforced in the US through FDAAA 801 and its implementing regulation, 42 CFR Part 11), or (3) makes the underlying protocol, statistical analysis plan, or individual participant-level data available for independent scrutiny (clinical data sharing). It is a movement and a set of overlapping obligations and voluntary commitments, not a single regulation -- a trial can satisfy one pillar (say, registration) while failing another (results reporting), which is precisely the gap transparency advocacy has spent over a decade trying to close.",
  "inDefinedTermSet": "https://casrai.org/dictionary/domain/clinical-research#set",
  "url": "https://casrai.org/dictionary/term/clinical-trial-transparency",
  "sameAs": [],
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "publisher": {
    "@id": "https://casrai.org/#organization"
  },
  "dateModified": "2026-07-23T07:55:09",
  "inLanguage": "en"
}